See more : Horace Mann Educators Corporation (HMN) Income Statement Analysis – Financial Results
Complete financial analysis of Jubilant Pharmova Limited (JUBLPHARMA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jubilant Pharmova Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fiskars Oyj Abp (FSKRS.HE) Income Statement Analysis – Financial Results
- Tung Ho Steel Enterprise Corporation (2006.TW) Income Statement Analysis – Financial Results
- CNP Assurances SA (CNPAY) Income Statement Analysis – Financial Results
- Suryo Foods & Industries Limited (SURFI.BO) Income Statement Analysis – Financial Results
- Ultralife Corporation (ULBI) Income Statement Analysis – Financial Results
Jubilant Pharmova Limited (JUBLPHARMA.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.jubilantpharmova.com
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.45B | 62.19B | 60.59B | 59.64B | 58.43B | 89.97B | 74.25B | 57.65B | 56.47B | 57.76B | 57.22B | 51.13B | 42.54B | 34.46B | 37.91B | 35.18B | 24.89B | 18.10B | 14.99B | 11.70B | 8.59B |
| Cost of Revenue | 47.39B | 22.23B | 17.87B | 17.53B | 16.48B | 38.21B | 31.44B | 22.52B | 23.71B | 29.18B | 26.87B | 22.79B | 16.12B | 18.45B | 14.92B | 31.31B | 11.69B | 9.69B | 8.37B | 9.63B | 4.38B |
| Gross Profit | 19.06B | 39.97B | 42.72B | 42.10B | 41.95B | 51.76B | 42.81B | 35.13B | 32.76B | 28.58B | 30.35B | 28.34B | 26.42B | 16.00B | 22.99B | 3.87B | 13.20B | 8.41B | 6.62B | 2.08B | 4.21B |
| Gross Profit Ratio | 28.69% | 64.26% | 70.51% | 70.60% | 71.79% | 57.53% | 57.66% | 60.94% | 58.01% | 49.47% | 53.04% | 55.43% | 62.12% | 46.44% | 60.64% | 11.01% | 53.02% | 46.46% | 44.14% | 17.74% | 49.03% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 185.05M | 202.20M | 182.05M | 161.64M | 131.16M | 71.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.26B | 2.23B | 2.46B | 2.32B | 2.19B | 2.68B | 1.46B | 1.02B | 971.38M | 1.24B | 1.06B | 812.42M | 6.84B | 1.80B | 3.83B | 4.22B | 3.34B | 2.70B | 2.28B | 1.86B | 1.46B |
| Selling & Marketing | 2.14B | 1.53B | 1.56B | 1.49B | 1.46B | 2.18B | 1.96B | 1.33B | 1.20B | 1.28B | 1.19B | 1.23B | 1.12B | 947.98M | 1.59B | 1.18B | 953.05M | 785.09M | 535.56M | 467.81M | 319.33M |
| SG&A | 14.45B | 3.76B | 4.02B | 3.81B | 3.64B | 4.85B | 3.42B | 2.35B | 2.17B | 2.52B | 2.26B | 2.05B | 7.95B | 2.75B | 5.42B | 5.40B | 4.29B | 3.49B | 2.82B | 2.33B | 1.78B |
| Other Expenses | 0.00 | 112.81M | 86.90M | 67.18M | 40.74M | 125.48M | 226.88M | 159.32M | 106.33M | 134.08M | 113.58M | 102.47M | 139.46M | -30.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.45B | 37.67B | 34.48B | 30.92B | 29.86B | 37.94B | 31.74B | 24.40B | 23.34B | 24.55B | 23.07B | 20.30B | 19.74B | 11.95B | 17.17B | -164.56M | 8.29B | 5.40B | 4.83B | 214.99M | 2.90B |
| Cost & Expenses | 61.82B | 59.89B | 52.35B | 48.45B | 46.34B | 76.15B | 63.17B | 46.92B | 47.05B | 53.74B | 49.94B | 43.09B | 35.86B | 30.40B | 32.09B | 31.14B | 19.98B | 15.09B | 13.20B | 9.84B | 7.28B |
| Interest Income | 261.00M | 98.28M | 24.51M | 80.97M | 189.46M | 109.68M | 51.30M | 87.79M | 27.39M | 62.40M | 52.20M | 113.05M | 161.95M | 0.00 | 50.54M | 0.00 | 267.03M | 0.00 | 55.30M | 0.00 | 0.00 |
| Interest Expense | 2.72B | 1.69B | 1.38B | 1.73B | 1.88B | 2.06B | 2.64B | 3.01B | 3.35B | 3.27B | 3.06B | 2.85B | 2.21B | 1.06B | 1.51B | 1.07B | 350.80M | 0.00 | 172.66M | 220.36M | 0.00 |
| Depreciation & Amortization | 3.82B | 5.54B | 3.82B | 3.49B | 3.40B | 3.71B | 3.24B | 2.88B | 3.47B | 2.88B | 2.81B | 2.54B | 2.21B | 1.93B | 1.41B | 1.63B | 1.04B | 1.04B | 513.35M | 394.82M | 326.18M |
| EBITDA | 8.09B | 7.58B | 11.68B | 13.93B | 15.52B | 14.93B | 14.67B | 13.66B | 12.39B | 6.96B | 10.30B | 8.36B | 5.61B | 5.96B | 8.10B | 5.67B | 5.82B | 4.02B | 2.30B | 2.26B | 1.62B |
| EBITDA Ratio | 12.17% | 13.10% | 19.04% | 25.51% | 29.03% | 19.73% | 20.67% | 23.18% | 21.84% | 11.81% | 17.63% | 20.83% | 21.30% | 17.28% | 21.36% | 16.11% | 23.37% | 22.21% | 15.34% | 19.28% | 18.91% |
| Operating Income | 5.19B | 2.07B | 8.25B | 11.10B | 12.50B | 13.38B | 11.30B | 10.05B | 9.17B | 3.94B | 7.27B | 8.11B | 6.85B | 4.03B | 6.68B | 4.04B | 4.78B | 2.98B | 1.79B | 1.86B | 1.30B |
| Operating Income Ratio | 7.81% | 3.33% | 13.62% | 18.61% | 21.40% | 14.88% | 15.21% | 17.43% | 16.23% | 6.83% | 12.71% | 15.87% | 16.11% | 11.69% | 17.63% | 11.47% | 19.19% | 16.46% | 11.92% | 15.91% | 15.11% |
| Total Other Income/Expenses | -3.48B | -2.01B | -19.38B | -17.47B | -1.95B | -4.78B | -2.70B | -3.36B | -4.00B | -3.62B | -5.21B | -4.63B | -5.54B | -1.65B | -639.93M | -1.07B | -343.98M | -26.62M | -104.96M | -220.36M | -343.93M |
| Income Before Tax | 1.71B | 277.81M | 6.30B | 8.71B | 10.13B | 9.04B | 8.59B | 7.38B | 5.42B | 403.24M | 2.07B | 3.41B | 1.14B | 2.41B | 5.18B | 2.97B | 4.56B | 2.95B | 1.68B | 1.64B | 966.28M |
| Income Before Tax Ratio | 2.57% | 0.45% | 10.40% | 14.61% | 17.34% | 10.05% | 11.57% | 12.79% | 9.60% | 0.70% | 3.62% | 6.67% | 2.68% | 6.98% | 13.66% | 8.43% | 18.33% | 16.32% | 11.22% | 14.02% | 11.25% |
| Income Tax Expense | 978.00M | 926.62M | 2.17B | 2.97B | 3.35B | 3.27B | 2.25B | 1.63B | 1.55B | 804.84M | 696.44M | 1.52B | 684.14M | 133.65M | 959.44M | 267.19M | -572.84M | -712.49M | -392.44M | 431.59M | -179.00M |
| Net Income | 771.00M | -609.80M | 4.14B | 8.36B | 8.98B | 5.74B | 6.43B | 5.76B | 3.92B | -577.64M | 1.09B | 1.53B | 145.61M | 2.30B | 4.21B | 2.83B | 4.00B | 2.28B | 1.30B | 1.19B | 782.37M |
| Net Income Ratio | 1.16% | -0.98% | 6.83% | 14.02% | 15.37% | 6.38% | 8.66% | 9.98% | 6.94% | -1.00% | 1.91% | 2.99% | 0.34% | 6.67% | 11.12% | 8.05% | 16.09% | 12.60% | 8.65% | 10.19% | 9.11% |
| EPS | 4.86 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 | 41.25 | 36.93 | 25.10 | -3.63 | 6.85 | 9.59 | 0.91 | 14.42 | 28.56 | 18.30 | 26.50 | 15.17 | 9.03 | 9.41 | 6.35 |
| EPS Diluted | 4.85 | -3.83 | 26.01 | 52.48 | 56.39 | 36.10 | 41.25 | 36.91 | 25.08 | -3.63 | 6.85 | 9.59 | 0.91 | 13.04 | 24.66 | 15.77 | 21.35 | 12.40 | 8.16 | 8.90 | 6.35 |
| Weighted Avg Shares Out | 158.51M | 159.15M | 159.17M | 159.27M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.28M | 159.28M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M |
| Weighted Avg Shares Out (Dil) | 158.86M | 159.15M | 159.17M | 159.27M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.28M | 159.28M | 159.28M | 159.28M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M | 159.13M |
Source: https://incomestatements.info
Category: Stock Reports